Clinical trial
Primary Rituximab and Maintenance
NCT00140582 · Lymphoma Study Association, Other · Completed
Key facts
| NCT number | NCT00140582 |
|---|---|
| Title | Primary Rituximab and Maintenance |
| Official title | Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy With Rituximab (MabThera®) After Induction of Response With Chemotherapy Plus Rituximab in Comparison With no Maintenance Therapy |
| Lead sponsor | Lymphoma Study Association, Other |
| Collaborators | HOVON - Dutch Haemato-Oncology Association German Low Grade Lymphoma Study Group Australasian Leukaemia and Lymphoma Group Institute of Cancer Research, United Kingdom |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Follicular Lymphoma |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 1,217 |
| Start date | Dec 1, 2004 |
| Primary completion | May 1, 2007 |
| Completion | Dec 1, 2016 |
| First posted | Sep 1, 2005 |
| Last update posted | Mar 13, 2017 |
| Countries | Argentina, Australia, Belgium, Brazil, Colombia, Denmark, France, Netherlands, New Zealand, Peru, Spain, Thailand |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: